Ying Huang1,2, Zoe Moodie1, Michal Juraska1, Youyi Fong1,2, Lindsay N Carpp1, Laurent Chambonneau3, Diana L Coronel4, Gustavo H Dayan5, Carlos A DiazGranados6, Peter B Gilbert1,7. 1. Vaccine and Infec tious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, 98109, USA. 2. Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, 98109, USA. 3. Global Biostatistical Sciences, Sanofi Pasteur, Marcy-l'Etoile, 69280, France. 4. Clinical Sciences, Sanofi Pasteur, Mexico City, 04000, Mexico. 5. Sanofi Pasteur, Swiftwater, PA, 18370, USA. 6. Sanofi Pasteur, Marcel Mérieux, Marcy l'Etoile, 69280, France. 7. Department of Biostatistics, University of Washington, Seattle, WA, 98195, USA.
Abstract
BACKGROUND: The recombinant tetravalent live-attenuated dengue vaccine based on the YF 17D vaccine virus backbone (CYD-TDV) demonstrated vaccine efficacy (VE) against symptomatic, virologically confirmed dengue of any serotype from month 13 to month 25 (VCD-DENV-AnyM13→M25) in the CYD14 (2-14-y-olds) and CYD15 (9-16-y-olds) phase 3 trials. Fifty percent plaque reduction neutralization test (PRNT50) titers are a potential surrogate for immunobridging VE to adults. METHODS: Using PRNT50 calibration datasets, we applied immunobridging approaches using baseline and/or M13 PRNT50 titers to estimate VE against VCD-DENV-AnyM0→M25 and against hospitalized VCD (HVCD)-DENV-AnyM0→M72 in hypothetical 18-45-y-old and 46-50-y-old CYD14 and CYD15 cohorts. RESULTS: Baseline and M13 geometric mean PRNT50 titers were greater in 18-45-y-olds and in 46-50-y-olds vs 9-16-y-olds for most comparisons. Estimated VE (95% CIs against VCD-DENV-AnyM0→M25 ranged from 75.3% to 90.9% (52.5% to 100%) for 18-45-y-olds and 74.8% to 92.0% (53.4% to 100%) for 46-50-y-olds. Estimated VE (95% CIs) against HVCD-DENV-AnyM0→M72 ranged from 58.8% to 78.1% (40.9 to 98.9%) for 18-45-y-olds and 57.2% to 78.4% (40.5 to 97.6%) for 46-50-y-olds. Corresponding predictions among baseline-seropositive individuals yielded comparable or higher VE estimates. CONCLUSIONS: VE M0→M25 against DENV-Any and VE against HVCD-DENV-AnyM0→M72 are both expected to be higher in 18-45 and 46-50-y-olds vs CYD14 and CYD15 9-16-y-olds.
BACKGROUND: The recombinant tetravalent live-attenuated dengue vaccine based on the YF 17D vaccine virus backbone (CYD-TDV) demonstrated vaccine efficacy (VE) against symptomatic, virologically confirmed dengue of any serotype from month 13 to month 25 (VCD-DENV-AnyM13→M25) in the CYD14 (2-14-y-olds) and CYD15 (9-16-y-olds) phase 3 trials. Fifty percent plaque reduction neutralization test (PRNT50) titers are a potential surrogate for immunobridging VE to adults. METHODS: Using PRNT50 calibration datasets, we applied immunobridging approaches using baseline and/or M13 PRNT50 titers to estimate VE against VCD-DENV-AnyM0→M25 and against hospitalized VCD (HVCD)-DENV-AnyM0→M72 in hypothetical 18-45-y-old and 46-50-y-old CYD14 and CYD15 cohorts. RESULTS: Baseline and M13 geometric mean PRNT50 titers were greater in 18-45-y-olds and in 46-50-y-olds vs 9-16-y-olds for most comparisons. Estimated VE (95% CIs against VCD-DENV-AnyM0→M25 ranged from 75.3% to 90.9% (52.5% to 100%) for 18-45-y-olds and 74.8% to 92.0% (53.4% to 100%) for 46-50-y-olds. Estimated VE (95% CIs) against HVCD-DENV-AnyM0→M72 ranged from 58.8% to 78.1% (40.9 to 98.9%) for 18-45-y-olds and 57.2% to 78.4% (40.5 to 97.6%) for 46-50-y-olds. Corresponding predictions among baseline-seropositive individuals yielded comparable or higher VE estimates. CONCLUSIONS: VE M0→M25 against DENV-Any and VE against HVCD-DENV-AnyM0→M72 are both expected to be higher in 18-45 and 46-50-y-olds vs CYD14 and CYD15 9-16-y-olds.
Authors: Luis Villar; Gustavo Horacio Dayan; José Luis Arredondo-García; Doris Maribel Rivera; Rivaldo Cunha; Carmen Deseda; Humberto Reynales; Maria Selma Costa; Javier Osvaldo Morales-Ramírez; Gabriel Carrasquilla; Luis Carlos Rey; Reynaldo Dietze; Kleber Luz; Enrique Rivas; Maria Consuelo Miranda Montoya; Margarita Cortés Supelano; Betzana Zambrano; Edith Langevin; Mark Boaz; Nadia Tornieporth; Melanie Saville; Fernando Noriega Journal: N Engl J Med Date: 2014-11-03 Impact factor: 91.245
Authors: Peter B Gilbert; Ying Huang; Michal Juraska; Zoe Moodie; Youyi Fong; Alexander Luedtke; Yingying Zhuang; Jason Shao; Lindsay N Carpp; Nicholas Jackson; Laurent Chambonneau; Alain Bouckenooghe; Betzana Zambrano; Carina Frago; Sophie Pallardy; Fernando Noriega Journal: Am J Trop Med Hyg Date: 2019-07 Impact factor: 2.345
Authors: Maria Rosario Capeding; Ngoc Huu Tran; Sri Rezeki S Hadinegoro; Hussain Imam H J Muhammad Ismail; Tawee Chotpitayasunondh; Mary Noreen Chua; Chan Quang Luong; Kusnandi Rusmil; Dewa Nyoman Wirawan; Revathy Nallusamy; Punnee Pitisuttithum; Usa Thisyakorn; In-Kyu Yoon; Diane van der Vliet; Edith Langevin; Thelma Laot; Yanee Hutagalung; Carina Frago; Mark Boaz; T Anh Wartel; Nadia G Tornieporth; Melanie Saville; Alain Bouckenooghe Journal: Lancet Date: 2014-07-10 Impact factor: 79.321
Authors: Saranya Sridhar; Alexander Luedtke; Edith Langevin; Ming Zhu; Matthew Bonaparte; Tifany Machabert; Stephen Savarino; Betzana Zambrano; Annick Moureau; Alena Khromava; Zoe Moodie; Ted Westling; Cesar Mascareñas; Carina Frago; Margarita Cortés; Danaya Chansinghakul; Fernando Noriega; Alain Bouckenooghe; Josh Chen; Su-Peing Ng; Peter B Gilbert; Sanjay Gurunathan; Carlos A DiazGranados Journal: N Engl J Med Date: 2018-06-13 Impact factor: 91.245
Authors: Jane P Messina; Oliver J Brady; Nick Golding; Moritz U G Kraemer; G R William Wint; Sarah E Ray; David M Pigott; Freya M Shearer; Kimberly Johnson; Lucas Earl; Laurie B Marczak; Shreya Shirude; Nicole Davis Weaver; Marius Gilbert; Raman Velayudhan; Peter Jones; Thomas Jaenisch; Thomas W Scott; Robert C Reiner; Simon I Hay Journal: Nat Microbiol Date: 2019-06-10 Impact factor: 17.745
Authors: Samir Bhatt; Peter W Gething; Oliver J Brady; Jane P Messina; Andrew W Farlow; Catherine L Moyes; John M Drake; John S Brownstein; Anne G Hoen; Osman Sankoh; Monica F Myers; Dylan B George; Thomas Jaenisch; G R William Wint; Cameron P Simmons; Thomas W Scott; Jeremy J Farrar; Simon I Hay Journal: Nature Date: 2013-04-07 Impact factor: 49.962
Authors: Tatyana M Timiryasova; Matthew I Bonaparte; Ping Luo; Rebecca Zedar; Branda T Hu; Stephen W Hildreth Journal: Am J Trop Med Hyg Date: 2013-03-04 Impact factor: 2.345